Logo of Flare Therapeutics

Flare Therapeutics

Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare Tx’s team has uncovered ‘switch sites’ druggable regions that are key targets for transcription factor regulation to address mutations that cause disease. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors and Eventide Asset Management. For more information, please visit www.flaretx.com.

Content by Flare Therapeutics

A computer being used for management
| 1 min read
Industry Perspectives
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A 3D rendering illustrates a sandwich ELISA technique, where antigen detection is achieved between two layers of antibodies: a capture antibody and a detection antibody
The four essentials of immunoassay quality
Learn the key characteristics that determine whether an immunoassay generates accurate and reproducible data.
Ebooks
R&D systems
Illustration of translucent Y-shaped antibodies floating in a soft blue and green background, representing antibody research, development, and biomedical science.
Solving the antibody access problem in translational research
Explore how antibody accessibility and custom development strategies can influence the pace and success of translational research.
Whitepaper
Logo of Bio X Cell
Digital illustration of a glowing DNA double helix surrounded by interconnected circuit-like lines on a dark blue background.
Understanding chemical and enzymatic DNA synthesis
Learn the key differences between chemical and enzymatic approaches to synthetic DNA production and their implications for modern research.
Articles
Ansa Technologies
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue